You are here: Home » International » News » Companies
Business Standard

UN program inks Moderna deal on 500mn doses, starting in Q4

Moderna and vaccine promoter Gavi have announced a firm deal to provide up to 500 million doses for the UN-backed program to ship coronavirus vaccines to needy people in low- and middle-income country

Topics
UN programme | Coronavirus Vaccine | Vaccine

AP  |  Geneva 

moderna, covid, vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab

Moderna and promoter Gavi have announced a firm deal by which the pharmaceutical company will provide up to 500 million doses for the UN-backed program to ship coronavirus vaccines to needy people in low- and middle-income countries by the end of 2022.

The advance purchase agreement announced on Monday comes just days after the World Health Organisation, after weeks of delays, announced emergency approval for the Moderna that will pave the way for its rollout in the UN-backed COVAX program.

However, deliveries are not set to begin until the fourth quarter of this year, and the vast majority of the doses in the deal 466 million are planned for next year. The remaining 34 million are expected this year.

Financial terms were not disclosed.

Many experts say the COVID-19 crisis is acute now, with India in particular facing an unprecedented surge in cases. The Moderna has generally been considered among the most effective so far in combating new variants, like the one that is spreading in India.

The arrangement means that Cambridge, Mass.-based Moderna can join the COVAX rollout that already includes vaccines from Oxford-AstraZeneca, which has the biggest role so far in the program, and Pfizer-BioNTech, which has committed far fewer doses to it.

Supplies of the AstraZeneca vaccine for COVAX that are being produced in India have been limited in recent month as the New Delhi government and the Indian subcontractor divert much of that production to combating the devastating at home.

The Coalition for Epidemic Preparedness and Innovation, a public-private partnership that co-manages COVAX with Gavi and WHO, made an early investment into the Moderna vaccine as the pandemic arose and the first official link-up between the company and the program has come nearly 18 months into the pandemic.

The WHO go-ahead for an emergency use listing for Moderna's vaccine, announced late Friday, took many months because of delays that WHO faced in getting data from the manufacturer.

Many countries without their own advanced medical regulatory and assessment offices rely on the WHO listing to decide whether to use vaccines. UN children's agency UNICEF also uses the listing to deploy vaccines in an emergency like the pandemic.

Moderna has struck supply agreements with many rich countries, which will have already received millions of doses of the vaccine.

Also Monday, Gavi announced that Sweden's government has committed to donate 1 million doses of the Oxford-AstraZeneca vaccine to help COVAX urgently address immediate-term supply delays.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 03 2021. 16:06 IST
RECOMMENDED FOR YOU
.